NCT06336642 Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology
| NCT ID | NCT06336642 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Dyspnea |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-06-11 |
| Primary Completion | 2030-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 150 participants in total. It began in 2024-06-11 with a primary completion date of 2030-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To learn about the effect of Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (SPOT-ON) treatment on the severity of shortness of breath in patients with cancer.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of cancer * Age 18 or older. * Admitted to a medical floor. * Dyspnea intensity at rest of at least 4 on a 0-10-point NRS (where 0 = none, 10 = worst). * Speak English or Spanish. Exclusion Criteria: * Hemodynamic instability requiring active Merit Team or ICU team involvement. * Delirium as per clinical team's assessment in the Electronic Health Record (EHR). * Severe hypoxemia (SpO2 \< 90% despite supplemental oxygen of up to 6 L/min). * Continuous positive airway pressure (CPAP) use for obstructive sleep apnea, actively using \>10 hours a day. * Respiratory failure necessitating mechanical ventilation (i.e., HFNC or NIV), and planned thoracentesis within 72 hours of enrollment. * Patients with known pregnancy.
Contact & Investigator
David Hui, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT06336642 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dyspnea. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06336642 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06336642 currently recruiting?
Yes, NCT06336642 is actively recruiting participants. Contact the research team at dhui@mdanderson.org for enrollment information.
Where is the NCT06336642 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06336642 clinical trial?
NCT06336642 is sponsored by M.D. Anderson Cancer Center. The principal investigator is David Hui, MD at M.D. Anderson Cancer Center. The trial plans to enroll 150 participants.